Bisphosphonate use in patients with lung cancer and bone metastases: Recommendations of a European expert panel

Journal of Thoracic Oncology

Volumn 4, Issue 10, 2009, Pages 1280-1288

  De Marinis, Filippo ^a,i   Eberhardt, Wilfried ^b   Harper, Peter G ^c   Sureda, Bartomeu Massuti ^d   Nackaerts, Kristiaan ^e   Soerensen, Jens Benn ^f   Syrigos, Kostas ^g   Trédaniel, Jean ^h  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c GUY S HOSPITAL   (United Kingdom)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Rigshospitalet   (Denmark)

^g SOTIRIA GENERAL HOSPITAL   (Greece)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ San Camillo Forlanini High Specialization Hospitals   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Lung cancer; Recommendations.; Skeletal related events

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANALGESIA; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG USE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION;

EID: 70349685313     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b68e5a     Document Type: Review

References (77)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
2. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-3571.
3. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003;25:2669-2708.
4. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(Suppl 8):1588-1594.
5. Kosteva J, Langer CJ. Incidence and distribution of skeletal metastases in NSCLC in the era of PET [abstract]. Lung Cancer 2004;46(Suppl 1):S45.9.
6. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57:229-232. (Pubitemid 47044952)
7. Kosteva J, Langer C. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol 2008;20:155-161.
8. Saad F. Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. Eur Urol Suppl 2007;6:683-688.
9. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
10. Saad F, Gleason DM, Murray R, et al; Zoledronic Acid Prostate Cancer Study Group Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882. (Pubitemid 38807610)
11. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16: 2038-2044.
12. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25:S10-S18.
13. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005; 4:31-37.
14. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34(6 Suppl 4):S17-S23.
15. Hirsh YJ, Saad F, Lipton A. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-236.
16. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
17. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
19. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-1445.
20. Penel N, Hollebecque A, Maynou C, et al. Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. Support Care Cancer 2008;16:1089-1093.
21. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 2006;17:986-989. (Pubitemid 43778991)
22. Kinnane N. Burden of bone disease. Eur J Oncol Nurs 2007;11(Suppl 2):S28-S31.
23. Wong WS, Fielding R. Eating ability predicts subsequent quality of life in Chinese patients with breast, liver, lung, or nasopharyngeal carcinoma: a longitudinal analysis. Acta Oncol 2008;47:71-80.
24. Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res 2007;26:307-312.
25. Kvale PA, Selecky PA, Prakash UB. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(Suppl 3):368S- 403S.
26. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
27. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
28. Kristensen B, Ejlertsen B, Groenvold M, et al; MF 4265 Study Group Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74.
29. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-3157.
30. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(Suppl 4):14-27.
31. Shipman CM, Vanderkerken K, Rogers MJ, et al. The potent bisphos-phonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br J Haematol 2000;111:283-286.
32. Russell RG, Bisaz S, Fleisch H, et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthrop-athy (chondrocalcinosis or pseudogout). Lancet 1970;2:899-902.
33. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1:27-39.
34. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661.
35. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12: 1358-1367.
36. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
37. Selander KS, Monkkonen J, Karhukorpi EK, Härkönen P, Hannuniemi R, Väänänen HK. Characteristics of clodronate-induced apoptosis in oste-oclasts and macrophages. Mol Pharmacol 1996;50:1127-1138.
38. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphospho-nates. J Pharmacol Exp Ther 2001;296:235-242.
39. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-257.
40. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomer-ase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-494.
41. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
42. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006;21:684-694.
43. Hatoum HT, Lin S, Lipton A, et al. The impact of zoledronic acid treatment on frequency of skeletal complications experienced and on follow-up duration post diagnsosis of bone metastasis in lung cancer patients. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2008;26:8106.
44. Kataja V, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii11-ii13.
45. Witte RS, Koeller J, Davis TE, et al. Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med 1987; 147:937-939.
46. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
47. NCCN. Practice Guidelines for Pain Treatment in Adult Cancer Patients, 2008. Available at: http://www.nccn.org/professionals/physician-gls/ PDF/pain.pdf.
48. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-432.
49. Nackaerts K, Langer CJ, Harper PG, et al. International consensus panel recommendations for the diagnosis of bone metastases from lung cancer. J Thorac Oncol 2008;3:4(Suppl 1):S73.
50. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii39 -ii40.
51. Schirrmeister H, Arslandemir C, Glatting G, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:964-968.
52. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. Breast 2006;15(Suppl 1):30-40.
53. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012.
54. Winter MC, Thorpe HC, Burkinshaw R, et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response- exploratory evidence for direct anti-tumor activity in breast cancer. SABCS (San Antonio Breast Cancer Symposium, Texas, USA) 2008:Abstract #5101.
55. Saad F. Presented at: ECCO-The European Cancer Conference, 2005. Paris, France. Abstract 1265.
56. Sculier JP, Meert AP. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2008;3:320.
57. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006;1:571-576.
58. Botteman MF, Marfatia AA, Groot MT, Langer CJ. Economic value of zoledronic acid versus placebo in the treatment of skeletal metas-tases in patients with lung cancer: applications to France and Germany [abstract]. Presented at 12th WCLC, Seoul, Korea, 2007. Abstract P1-P262.
59. Botteman MF, Kaura S. Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: applications to UK and Germany [abstract]. J Thorac Oncol 2008;3:Abstract 201 PD.
60. Botteman MF, Foley I, Marfatia AA, et al. Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: the case of the United Kingdom (UK) [abstract]. J Clin Oncol 2007;25 (Suppl 18):6617.
61. Major P. Optimal management of metastatic bone disease. Eur J Oncol Nurs 2007;11(Suppl 2):S32-S37.
62. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-145.
63. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-120.
64. Gnant M, Mlineritsch B, Schippinger W, et al; ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:279-291.
65. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008;34(Suppl 1):S19-S24.
66. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4974.
67. Mystakidou K, Katsouda E, Parpa E, et al. A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. Am J Hosp Palliat Care 2006;23:41-50.
68. Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W. [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study]. Dtsch Med Wochenschr 2008;133:285-289.
69. Santini D, Schiavon G, Angeletti S, et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs? Recent Pat Anticancer Drug Discov 2006;1:383-396.
70. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-151.
71. Mariani S, Muraro M, Pantaleoni F, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005;19:664-670.
72. Santini D, Vincenzi B, Hannon RA, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 2006;15:1351-1357.
73. Li YY, Chang JW, Chou WC, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008;59:180-191.
74. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-969.
75. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letro-zole: ZO-FAST Study results. Cancer 2008;112:1001-1010.
76. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer 2004;100:2613-2621.
77. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-1884.